SEC Form SC 13G filed by Sight Sciences Inc.

$SGHT
Medical/Dental Instruments
Health Care
Get the next $SGHT alert in real time by email
SC 13G 1 d412734dsc13g.htm SC 13G SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

 

Sight Sciences, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

82657M105

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


  1    

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  KCK Ltd.

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☐

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  British Virgin Islands

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5    

  SOLE VOTING POWER

 

  0

   6  

  SHARED VOTING POWER

 

  4,776,232

   7  

  SOLE DISPOSITIVE POWER

 

  0

   8  

  SHARED DISPOSITIVE POWER

 

  4,776,232

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  4,776,232

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  9.9%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  OO


  1    

  NAMES OF REPORTING PERSONS

  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

  Nael Karim Kassar

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☐

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  France

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5    

  SOLE VOTING POWER

 

  0

   6  

  SHARED VOTING POWER

 

  4,776,232

   7  

  SOLE DISPOSITIVE POWER

 

  0

   8  

  SHARED DISPOSITIVE POWER

 

  4,776,232

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  4,776,232

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  9.9%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IN


Item 1(a).

Name of Issuer:

Sight Sciences, Inc. (the “Issuer”)

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

4040 Campbell Ave., Suite 100

Menlo Park, CA 94025

 

Item 2(a).

Names of Persons Filing:

The names of the persons filing this report (the “Reporting Person”) are:

KCK Ltd.

Nael Karim Kassar

 

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

KCK Ltd.

Corner House

20 Parliament Street

Hamilton, Bermuda HM12

 

Item 2(c).

Citizenship:

KCK Ltd.:                      British Virgin Islands

Nael Karim Kassar:       France

 

Item 2(d).

Title of Class of Securities:

Common Stock, $0.001 par value per share (“Common Stock”)

 

Item 2(e).

CUSIP Number:

82657M105

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

 

Item 4.

Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentage reported is based on 48,151,302 outstanding shares of Common Stock, as reported in the Issuer’s Form 10-Q filed on November 10, 2022.

KCK Ltd., through a board of directors consisting of three or more persons, has sole voting power and investment power with respect to the shares of Common Stock held by KCK Ltd. Nael Karim Kassar is the chief executive officer of KCK Ltd.


Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

Not applicable.

 

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date:    February 13, 2023

 

KCK LTD.
By:  

/s/ Raphael Metz

 

Raphael Metz

Secretary

NAEL KARIM KASSAR
By:  

/s/ Nael Karim Kassar

  Nael Karim Kassar, individually


JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of February 13, 2023, is by and among KCK Ltd. and Nael Karim Kassar (collectively, the “Filers”).

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to Common Stock of Sight Sciences, Inc. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

 

KCK LTD.
By:  

/s/ Raphael Metz

 

Raphael Metz

Secretary

NAEL KARIM KASSAR
By:  

/s/ Nael Karim Kassar

  Nael Karim Kassar, individually
Get the next $SGHT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SGHT

DatePrice TargetRatingAnalyst
12/6/2024$5.50Buy
UBS
11/4/2024$10.00 → $5.00Buy → Hold
Lake Street
8/21/2024$10.00Buy
Lake Street
9/12/2023$10.00 → $4.50Neutral → Underperform
BofA Securities
9/12/2023$15.00 → $5.50Overweight → Neutral
Piper Sandler
9/12/2023Outperform → Mkt Perform
William Blair
8/24/2023$12.00 → $8.40Overweight → Equal-Weight
Morgan Stanley
7/10/2023$15.00 → $9.00Buy → Neutral
Citigroup
More analyst ratings

$SGHT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

    MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. Sight Sciences' management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the Company's website at https://investors.sightsciences.com/. About Sight Sc

    $SGHT
    Medical/Dental Instruments
    Health Care
  • Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

    MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg

    $SGHT
    Medical/Dental Instruments
    Health Care
  • Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

    A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System MENLO PARK, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced that multiple presentations on the OMNI® Surgical System ("OMNI") will be presented at the 2025 American Glaucoma Society ("AGS") Annual Meeting in W

    $SGHT
    Medical/Dental Instruments
    Health Care

$SGHT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SGHT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SGHT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SGHT
SEC Filings

See more

$SGHT
Leadership Updates

Live Leadership Updates

See more
  • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
  • Sight Sciences Appoints Matt Link as Chief Commercial Officer

    MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth

    $SGHT
    Medical/Dental Instruments
    Health Care
  • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology

$SGHT
Financials

Live finance-specific insights

See more
  • Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

    MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg

    $SGHT
    Medical/Dental Instruments
    Health Care
  • Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

    MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the even

    $SGHT
    Medical/Dental Instruments
    Health Care
  • Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the third quarter ended September 30, 2024, and updated its adjusted operating expenses guidance for full year 2024. Third Quarter 2024 Financial and Business Highlights Generated total revenue of $20.2 million, an increase of 1% compared to the same period in the prior year.Generated positive cash flow of $0.4 million, a substantial improvement compared to $10.0 million cash used in

    $SGHT
    Medical/Dental Instruments
    Health Care

$SGHT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more